Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Aerie Pharmaceuticals Rose as Much as 21.8% Today

By Maxx Chatsko - Oct 11, 2019 at 1:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new slide deck shows reasons for optimism.

What happened

Shares of Aerie Pharmaceuticals (AERI 1.47%) jumped nearly 22% today after the company published an October investor presentation. The slide deck indicates that the ophthalmology, or eye-focused, pharma experienced a surge in the number of bottles of Rhopressa and Rocklatan shipped to pharmacies in the week ending Oct. 4.

Investors usually have to wait for prescription and bottle data sets from IQVIA to be published to gauge the trajectory of recent drug launches, but the latest numbers from IQVIA end on Sept. 27. Therefore, the surge in total product shipped is giving investors reason to cheer, especially after a surprisingly sluggish start.

As of 1:01 p.m. EDT, the stock had settled to a 17% gain.

A woman checking her phone and pumping her fist in excitement as cash falls around her.

Image source: Getty Images.

So what

Rhopressa is a rho kinase, or ROCK, inhibitor approved to reduce intraocular pressure (IOP) in individuals with glaucoma. Rocklatan is a combination of the active pharmaceutical ingredient in Rhopressa and latanoprost that launched in May 2019. Analysts estimate that Rhopressa could have peak annual sales of about $400 million, while Rocklatan could come close to $1 billion.

Aerie Pharmaceuticals had originally expected full-year 2019 revenue of $115 million at the midpoint but had to walk that back to just $75 million after experiencing slower-than-expected sales trajectories for its franchise in the first six months of the year. The sudden surge in sales -- driven by Rocklatan, it appears -- to pharmacies in the first week of October won't reverse that, but it's a good sign nonetheless.

Now what

The recent update suggests Aerie Pharmaceuticals can get its drug products back on a promising trajectory after all. Investors would certainly welcome that, especially after seeing the pharma stock fall nearly 60% in the last year. That said, investors shouldn't rely too heavily on week-to-week updates and should instead focus on the long-term trajectory of the company.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aerie Pharmaceuticals, Inc. Stock Quote
Aerie Pharmaceuticals, Inc.
AERI
$11.74 (1.47%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.